Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CBIO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 | Locally Advanced / Metastatic Solid Tumors | Phase 1/2 · NCT07335497 | Recruiting |
| CR-002 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic… | Phase 1/2 · NCT07909031 | Recruiting |
| FOLFOX | Locally Advanced / Metastatic Solid Tumors | Phase 1/2 · NCT07335497 | Recruiting |
| Gemcitabin | Locally Advanced / Metastatic Solid Tumors | Phase 1/2 · NCT07335497 | Recruiting |
Also used in these trials (approved or third-party drugs, not CBIO's own candidates): Capecitabine, Carboplatin, Cisplatin, Oxaliplatin, Paclitaxel, Pemetrexed Disodium, Trifluridine And Tipiracil.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CBIO holds $289.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.2M/quarter from operations, an estimated runway of 37.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CBIO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Peter Harwin | 5%+ holder (13D) | 6,602,408 | 16.97% | 2026-07-16 |
| FMR LLC | Institution (13G, 5%+) | 4,133,514 | 10.63% | 2025-12-31 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 3,691,518 | 9.49% | 2026-09-30 |
| Fairmount Funds Management LLC Director, 10% owner · +2.31M options |
Insider | 3,601,316 | 9.26% | 2026-07-16 |
| Vestal Point Capital, LP | Institution (13G, 5%+) | 3,000,000 | 7.71% | 2026-09-30 |
| Venrock Healthcare Capital Partners III, | 5%+ holder (13G) | 2,228,641 | 5.73% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,075,291 | 5.34% | 2026-09-30 |
| ForGrowth III PA B.V. | 5%+ holder (13G) | 1,677,852 | 4.31% | 2025-12-08 |
| Joshua T Brumm Chief Executive Officer, Director · +526,139 options |
Insider | 271,765 | 0.70% | 2026-09-16 |
| Jonathan McNeill President and COO · +250,865 options |
Insider | 134,588 | 0.35% | 2026-09-16 |
| Christopher Grant Doughty Chief Business Officer · +58,855 options |
Insider | 62,194 | 0.16% | 2025-12-15 |
| Jan Pinkas Chief Scientific Officer · +212,499 options |
Insider | 21,581 | 0.06% | 2026-09-16 |
Share count 38,895,442 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CBIO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →